The Cancer and Hematology Centers
Welcome,         Profile    Billing    Logout  
 19 Trials 
83 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khushalani, Nikhil
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
06/28
06/28
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Active, not recruiting
2
26
US
Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
09/25
09/26
NCT04996823: Axitinib + Ipilimumab in Advanced Melanoma

Recruiting
2
25
US
Ipilimumab, Yervoy, Axitinib, Inlyta
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma
03/26
03/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Recruiting
2
37
US
Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Uveal Melanoma, Ocular Melanoma
07/26
07/26
HBI-8000-302, NCT02718066: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Checkmark Presentation of data in combination with Opdivo in patients with advanced metastatic melanoma at SITC 2020
Nov 2020 - Nov 2020: Presentation of data in combination with Opdivo in patients with advanced metastatic melanoma at SITC 2020
Completed
1b/2
96
US
HBI-8000 in combination with nivolumab, For HBI-8000: Chidamide, CS055; for nivolumab: OPDIVO
HUYABIO International, LLC.
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
09/23
09/23
ARTACUS, NCT04349436: A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

Recruiting
1/2
65
US
RP1, intra-tumoral injection, oncolytic virus
Replimune Inc.
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
09/27
01/28
NCT01176474: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
73
US
NY-ESO-1 157-165 (165V), NSC 717388, peptide vaccine, NY-ESO-1, ESO-165V Peptide, Nivolumab, BMS-936558, NSC 748726, Anti PD-1, antibody, MDX-1106, Immunotherapy, HMA, gp100:280-288 (288V), NSC 683473, Peptide, g9-288-9V Peptide, Montanide ISA 51 vegetable grade (VG), NSC 737063, Ipilimumab, NSC 732442, Apheresis Procedure
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Medarex, Bristol-Myers Squibb
Melanoma (Skin)
08/20
01/23
MTI201-IA, NCT05496686: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Recruiting
1
16
US
4.7 microCi 225Ac-MTI-201, 4.7 microCi 225Actinium-MTI-201, 9.5 microCi of 225Ac-MTI-201, 9.5 microCi 225Actinium-MTI-201, 19 microCi of 225Ac-MTI-201, 19 microCi 225Actinium-MTI-201, 38 microCi of 225Ac-MTI-201, 38 microCi 225Actinium-MTI-201, 76 microCi of 225Ac-MTI-201, 76 microCi 225Actinium-MTI-201, 152 microCi of 225Ac-MTI-201, 152 microCi 225Actinium-MTI-201, 254 microCi of 225Ac-MTI-201, 254 microCi 225Actinium-MTI-201, 424 microCi of 225Ac-MTI-201, 424 microCi 225Actinium-MTI-201, 564 microCi of 225Ac-MTI-201, 564 microCi 225Actinium-MTI-201, 750 microCi of 225Ac-MTI-201, 750 microCi 225Actinium-MTI-201, 998 microCi of 225Ac-MTI-201, 998 microCi 225Actinium-MTI-201, 1327 microCi of 225Ac-MTI-201, 1327 microCi 225Actinium-MTI-201
Modulation Therapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma, Metastatic
04/25
02/29
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
1
30
US
Cemiplimab-Rwlc, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
06/27
06/27
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Active, not recruiting
1
16
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Metastatic Melanoma, Metastasis to Brain
06/24
06/25
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Recruiting
1
34
US
Vismodegib 150 MG Oral Capsule, Erivedge
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
Advanced Basal Cell Carcinoma
12/28
12/29
Carvajal, Richard
ATOM, NCT06246149: Adjuvant Tebentafusp in High Risk Ocular Melanoma

Recruiting
3
290
Europe
Tebentafusp
European Organisation for Research and Treatment of Cancer - EORTC, Northwell Health, Immunocore Ltd
Uveal Melanoma
11/32
11/32
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT02223819: Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Completed
2
34
US
Crizotinib, Xalkori
Columbia University, Pfizer
Uveal Melanoma
07/19
07/19
NCT04807777: Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Terminated
2
3
US
Ruxolitinib, JAKAVI
Columbia University, Incyte Corporation
Advanced Cutaneous Squamous Cell Carcinoma
04/23
10/23
NCT03944941: Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer

Active, not recruiting
2
60
US
Avelumab, Cetuximab
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
11/26
12/28
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
MUM, NCT03947385: Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Jan 2023 - Dec 2023: Data from P1/2 trial in combination with crizotinib for treatment of MUM
Checkmark Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Sep 2022 - Sep 2022: Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Checkmark From trial in combination with darovasertib for uveal melanoma
Dec 2021 - Dec 2021: From trial in combination with darovasertib for uveal melanoma
Recruiting
1/2
341
Canada, US, RoW
IDE196, Protein Kinase C (PKC) Inhibitor, Binimetinib, MEKTOVI, Crizotinib, XALKORI
IDEAYA Biosciences
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
12/26
03/27
BT7480-100, NCT05163041: Study in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Recruiting
1/2
200
Europe, US
BT7480, Nivolumab
BicycleTx Limited
Advanced Solid Tumor
09/25
12/25
NCT02768766: Intermittent Selumetinib for Uveal Melanoma

Completed
1
42
US
Selumetinib, 100mg, hyd-sulfate AZD6244, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg
Shaheer A. Khan, AstraZeneca, Melanoma Research Alliance
Uveal Melanoma
09/20
09/20
CS5001-101, NCT05279300: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Hourglass Sep 2024 - Sep 2024 : Data for adv solid tumors
Recruiting
1
156
US, RoW
CS5001
CStone Pharmaceuticals
Advanced Solid Tumor, Advanced Lymphoma
03/25
06/25
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Recruiting
1
292
Canada, US, RoW
BCA101, Ficerafusp alfa, Pembrolizumab
Bicara Therapeutics, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
12/26
06/27
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting
N/A
700
Europe, Canada, US, RoW
Columbia University
Uveal Melanoma
07/26
07/26
Maurer, Matthew
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05635045: Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

Completed
2
25
US
I 124-Evuzamitide, Attralus AT-01
Columbia University, Attralus, Inc.
Transthyretin Amyloidosis
05/24
06/24
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
MUM, NCT03947385: Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Jan 2023 - Dec 2023: Data from P1/2 trial in combination with crizotinib for treatment of MUM
Checkmark Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Sep 2022 - Sep 2022: Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Checkmark From trial in combination with darovasertib for uveal melanoma
Dec 2021 - Dec 2021: From trial in combination with darovasertib for uveal melanoma
Recruiting
1/2
341
Canada, US, RoW
IDE196, Protein Kinase C (PKC) Inhibitor, Binimetinib, MEKTOVI, Crizotinib, XALKORI
IDEAYA Biosciences
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
12/26
03/27
MTX-GPC3-303, NCT06478693: A Study of MT-303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Recruiting
1
48
RoW
MT-303
Myeloid Therapeutics
Hepatocellular Carcinoma
07/25
05/26
MYE Symphony, NCT05969041: Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Recruiting
1
48
RoW
MT-302 (A)
Myeloid Therapeutics
Epithelial Tumors, Malignant
08/27
08/28
Orloff, Marlana M
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT03472586: Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Active, not recruiting
2
14
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, 720801, 477202-00-9, 732442, Nivolumab, 946414-94-4, BMS-936558, ONO-4538, Opdivo, Embolization Therapy
Sidney Kimmel Cancer Center at Thomas Jefferson University, Bristol-Myers Squibb
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
12/22
12/24
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Withdrawn
1/2
113
US
Tebentafusp (IMCgp100)
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
MUM, NCT03947385: Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Jan 2023 - Dec 2023: Data from P1/2 trial in combination with crizotinib for treatment of MUM
Checkmark Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Sep 2022 - Sep 2022: Interim data from trial in combination with crizotinib for metastatic uveal melanoma
Checkmark From trial in combination with darovasertib for uveal melanoma
Dec 2021 - Dec 2021: From trial in combination with darovasertib for uveal melanoma
Recruiting
1/2
341
Canada, US, RoW
IDE196, Protein Kinase C (PKC) Inhibitor, Binimetinib, MEKTOVI, Crizotinib, XALKORI
IDEAYA Biosciences
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
12/26
03/27
NCT06626516: Tebentafusp-tebn With LDT in Metastatic UM

Not yet recruiting
1/2
109
US
Tebentafusp-Tebn, kimmtrak, IMCgp100, GM-CSF (Sargramostim), yeast-derived recombinant human GM-CSF, Leukine, Hepatic Immunoembolization, GM-CSF, Sargramostim, BCNU, Carmustine, BiCNU, bis-chloroethylnitrosourea, Hepatic Chemoembolization, 1,3-bis [2-chloroethyl]-1-nitrosourea
Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University
Metastatic Uveal Melanoma
07/26
08/26
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting
N/A
700
Europe, Canada, US, RoW
Columbia University
Uveal Melanoma
07/26
07/26
Miller, Jessica M
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
Haas, Denise
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
Rose, Amy
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT04493203 / 2005-001438-34: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Active, not recruiting
2
31
US
Nivolumab, Opdivo, AG013736, Axitinib, INLYTA
Yana Najjar, Pfizer, Bristol-Myers Squibb
Advanced Melanoma, Unresectable Melanoma
04/24
02/29
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT04808999: Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Active, not recruiting
2
30
US
Pembrolizumab Injection, Keytura
Diwakar Davar, Merck Sharp & Dohme LLC
Squamous Cell Carcinoma
04/24
04/29
Neo-MEL-T, NCT04139902: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) Vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Recruiting
2
62
US
Dostarlimab (TSR-042) (singly), Dostarlimab, Dostarlimab (TSR-042) and TSR-022 (combination)
Diwakar Davar, Tesaro, Inc.
Melanoma Stage III, Melanoma Stage IV
09/25
04/29
NCT05130177: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Recruiting
2
26
US
Zimberelimab, AB122, Domvanalimab, AB154
Diwakar Davar, Arcus Biosciences, Inc.
Melanoma
01/27
01/30
FMT-ELIMINATE, NCT06499896: Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)

Recruiting
2
30
US
MTP-101-C
Diwakar Davar, Stanley Marks Fund for Cancer Research, Cures Within Reach
Immune-mediated Colitis (IMC), Immune-related Dermatitis
09/26
09/30
NCT06030037: Pembrolizumab/Lenvatinib with and Without Responder-derived FMT in Relapsed/Refractory Melanoma

Not yet recruiting
2
56
US
Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab, Lenvatinib
Diwakar Davar, Merck Sharp & Dohme LLC, Gateway for Cancer Research
PD-1 Refractory Advanced Melanoma
12/29
12/29
NCT05061017: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Completed
2
14
US
Pixatimod, (PG545), Nivolumab, OPDIVO®, Cyclophosphamide (low dose)
Diwakar Davar, Aculeus Therapeutics
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
02/24
03/24
NCT06070012: Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Not yet recruiting
2
44
US
Tebentafusp, Kimmtrak
Diwakar Davar, Immunocore Ltd
Uveal Melanoma
11/26
11/29
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT04401995: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

Completed
2
9
US
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Diwakar Davar, Checkmate Pharmaceuticals, CellSight Technologies, Inc.
Melanoma
08/24
08/24
NCT05669846: Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC

Recruiting
2
26
US
Fecal Microbiota Transplant (FMT), Pembrolizumab, Keytruda
Diwakar Davar, Gateway for Cancer Research
Non Small Cell Lung Cancer
12/29
12/29
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NCT04074967: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Checkmark Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Nov 2022 - Nov 2022: Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Active, not recruiting
1/2
70
US
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Jason J. Luke, MD, Array BioPharma
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
11/27
11/27
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
NCT06216938: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting
1
25
US
Vusolimogene oderparepvec (RP1)
Yana Najjar, Replimune Inc.
Melanoma
01/26
07/28
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
NCT04572451: Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Recruiting
1
50
US
nivolumab, Opdivo®, Anti-PD-1, BMS-986253, Anti-IL-8, Stereotactic Body Radiotherapy (SBRT)
Jason J. Luke, MD, Bristol-Myers Squibb
Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
05/24
05/27
NCT03311308: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Recruiting
1
30
US
Pembrolizumab Injection [Keytruda], Keytruda, Metformin
Yana Najjar, Merck Sharp & Dohme LLC
Advanced Melanoma
01/27
12/28
NCT06599619: Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting
N/A
30
US
Nivolumab, OPDIVO®, Pembrolizumab, Keytruda
John Kirkwood, Melanoma Research Foundation
Melanoma
12/25
12/25
NCT04658303: Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting
N/A
20
US
Pimonidazole
Yana Najjar
Melanoma
03/27
03/27
Montazeri, Kamaneh
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
IMM6415-101, NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Hourglass Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases
Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
Cannon, Sarah
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
Javed, Asad
RP2-202, NCT06581406: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting
2/3
280
US
RP2, Ipilimumab, Yervoy, Nivolumab, Opdivo
Replimune Inc.
Metastatic Uveal Melanoma
01/30
10/31
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
11/26
11/26
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
Centers, The Cancer and Hematology
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
Department, Central Research
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28

Download Options